%A YU Fa-Chang, LI Sheng, NIU Zuo-Xing %T K-ras gene and colorectal cancer therapeutic effect %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.01.017 %P 214-216 %V 41 %N 3 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9335.shtml} %8 2014-03-08 %X K-ras gene is one of oncogenes, which promotes cells growth and differentiation. Ras protein loses the activity of GTP enzyme because of K-ras mutations, and that may cause abnormal growth, differentiation of cells and promote the occurrence of tumor. Patients with colorectal carcinoma that carry mutations in K-ras gene do not benefit from the administration of antiepidermal growth factor receptor (EGFR) polyclonal antibodies. Different solid tumors of colorectal carcinoma have different K-ras mutation rates. Different genotypes of K-ras gene (wildtype or K-ras mutant type) affect significantly on treatment options and prognosis. The efficacy of mutant type patients with antiEGFR antibodies is poor, and the therapeutic effects of 5-FU and FOLFOX are still unclear.